9 reports

Abstract: - Global RNA Interference (RNAi) Market to Reach $55.6 Billion by 2027 - Amid the COVID-19 crisis, the global market for RNA Interference (RNAi) estimated at US$21.2 Billion in the year 2020, is projected to reach a revised size of US$55.6 Billion by 2027, growing at a CAGR of 14.7% over the analysis period...

  • RNA
  • World
  • China
  • United States

landscape of RNA modifications.

  • RNA
  • RNAi Technology
  • United States
  • World
  • Drug Approval
  • Diagnostic Imaging Density

UNSTABLE POTENTIALLY IMMUNOGENIC NATURE OF RNA

  • RNA
  • APAC
  • World
  • Europe
  • Cancer Incidence
  • Drug Approval

23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021 Summary 23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021 provides in depth analysis on 23S Ribosomal RNA (23S rRNA) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications,...

  • RNA
  • World

16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021 Summary 16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021 provides in depth analysis on 16S Ribosomal RNA (16S rRNA) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications,...

  • RNA
  • World

This study covers the world outlook for RNA interference (RNAi) technologies across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These...

  • RNA
  • World
  • Gross Domestic Product
  • Disposable Income

This study covers the world outlook for antisense and RNA interference (RNAi) therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and...

  • RNA
  • Antisense Technology
  • World
  • Gross Domestic Product
  • Disposable Income

“Protein 50S ribosomal subunit inhibitors– Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Protein 50S ribosomal subunit inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment...

  • Anti-Infective
  • Genome Sequencing
  • Antiseptics
  • Drug Development
  • Clinical Trial
  • Monoclonal Antibody
  • Therapy
  • Biopharmaceutical
  • Analgesic
  • RNA
  • China
  • World

Deal Report: Traversa receives QTDP grant for RNA interference-based drug candidates

  • Drug Development
  • Private Placement
  • Therapy
  • RNA
  • United States
  • Dates Price